22 Results

People

  1. Giralt
    Giralt
  2. Korde
    Korde
  3. Usmani
    Usmani
  4. Hassoun
    Hassoun
  5. Landau
    Landau
  6. Landgren
    Landgren
  7. Lesokhin
    Lesokhin
  8. Shah
    Shah
  9. Chung
    Chung
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (17)
  2. Hematologic Malignancies, Division of (16)
  3. Center for Hematologic Malignancies (15)
  4. Bone Marrow Transplant (8)
  5. Survivorship Research (7)
  6. Myeloma (6)
  7. CTCR Scholars (3)
  8. Hematologic Malignancies Research (3)
  9. Lymphoma (3)
  10. Hematology-Oncology Fellows (2)
  1. "ixazomib"
Formats
  1. Journal Article (12)
  2. Review (6)
  3. Conference Paper (1)
  4. Correspondence (1)
  5. Meeting Abstract (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (17)
  2. Hematologic Malignancies, Division of (16)
  3. Center for Hematologic Malignancies (15)
  4. Bone Marrow Transplant (8)
  5. Survivorship Research (7)
  6. Myeloma (6)

More Groups

People
  1. Sergio Giralt (5)
  2. Neha Korde (4)
  3. Saad Usmani (4)
  4. Alexander Lesokhin (3)
  5. Carl Landgren (3)
  6. Hani Hassoun (3)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (7)
  4. 2022 (2)
  5. 2021 (2)
  6. 2020 (3)

More Years

Publications
  1. American Journal of Hematology (3)
  2. Clinical Lymphoma, Myeloma and Leukemia (3)
  3. Blood Advances (2)
  4. Seminars in Hematology (2)
  5. The Lancet Haematology (2)
  6. Best Practice and Research: Clinical Haematology (1)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. John Wiley & Sons, Inc. (3)
  3. American Society of Hematology (2)
  4. Elsevier Science, Inc. (2)
  5. Nature Publishing Group (2)
  6. W.B. Saunders Co-Elsevier Inc. (2)

More Publishers

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Alliance A061202: Ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse
    Journal Article

    Voorhees, P.; Suman, V.; Efebera, Y.; Raje, N.; Tuchman, S.; Rodriguez, C.; Laubach, J.; Bova-Solem, M.; Carlisle, D.; Usmani, S.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis
    Journal Article

    Costa, B. A.; Costa, T. A.; Saravia, S. D.; Felix, N.; Tan, C. R.; Korde, N.; Richter, J.
    American Journal of Hematology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
    Review

    Korde, N.; Usmani, S. Z.
    Hematology-Oncology and Stem Cell Therapy (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Future directions in the frontline management of Waldenström macroglobulinemia
    Review

    Buske, C.; Palomba, M. L.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis
    Journal Article

    Ragon, B. K.; Shah, M. V.; D’Souza, A.; Estrada-Merly, N.; Gowda, L.; George, G.; de Lima, M.; Hashmi, S.; Kharfan-Dabaja, M. A.; Majhail, N. S.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • A multicenter phase II, double-blind, placebo-controlled trial of maintenance ixazomib after allogeneic transplantation for high-risk multiple myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 trial
    Journal Article

    Bashir, Q.; Nishihori, T.; Pasquini, M. C.; Martens, M. J.; Wu, J.; Alsina, M.; Anasetti, C.; Brunstein, C.; Dawson, P.; Efebera, Y.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice
    Journal Article

    Sanchorawala, V.; Wechalekar, A. D.; Kim, K.; Schönland, S. O.; Landau, H. J.; Kwok, F.; Suzuki, K.; Dispenzieri, A.; Merlini, G.; Comenzo, R. L.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save